The online-GLP-1 category is five business models wearing eleven brands — and once you see the models, every provider’s marketing translates instantly. This is the complete map: every tracked provider, sorted by what it actually sells, with verification status attached and the shopping method that works across all of them.
Five models cover the category: flat-rate compounded (NexLife — verified — and Henry Meds), brand-access/insurance-first (Ro, Found), specialist membership (Mochi Health), mass DTC platforms (Hims, Hers, Orderly Meds), and the thin-documentation tier (Remedy Meds, Shed, Fifty 410). Pick the model that matches your constraint — coverage, complexity, certainty, or cash — then verify the specific provider with the checklist and the calculator.
Model 1: flat-rate, all-in compounded
One number, medication-inclusive, teaser-proof by construction — when the number is real. NexLife — the flat-rate compounded model, and currently the only provider with checkout-verified figures on this site: $139–169/month tirzepatide and $119–139 semaglutide by term, $0 fees observed, CARE360 support included, rate-locked (captured 2026-08-20). Watch-for: its ODT formats carry our standing no-outcome-trials flag. Rubric score 9.1 — the only score published, because scores require verified inputs.
Henry Meds — the best-known flat-rate compounded claim in the market. We favor the structure on principle (flat rates kill teaser math); whether the advertised number survives membership terms, shipping, and dose reality is exactly what its pending verification will test.
Model 2: brand-access and insurance-first
Sell the paperwork and the certainty: coverage navigation, prior-auth muscle, manufacturer-priced brand product when insurance fails. Ro — the brand-access and insurance-navigation play: coverage checks, prior-auth support, and a lane to Lilly’s Zepbound vials at manufacturer self-pay pricing. Structural strengths are product certainty and paperwork muscle; its own fee stack and all-in totals remain pending verification.
Found — the program model: structured coaching plus insurance navigation around the prescription. A genuinely different product than medication funnels; the program-fee-versus-medication split is the pending question.
Model 3: specialist membership
Sell the clinician: obesity-medicine depth on subscription, medication priced separately. Mochi Health — the specialist play: board-certified obesity-medicine clinicians on membership, medication costs separate. The bet is that titration judgment and comorbidity depth are worth paying for distinctly; membership-plus-medication totals pending.
Model 4: mass-market DTC platforms
Sell reach and friction-free checkout, multiplied across SKUs — where pricing complexity and legal-lane questions concentrate. Hims — the category’s marketing heavyweight, running “personalized” compounded semaglutide since the June 2025 Novo split — the legal lane regulators contest most directly. Aggressive entry pricing; maintenance-dose truth pending verification.
Hers — Hims’ women-positioned sibling: same platform, same post-Novo compounded posture, wrapped in women’s-health framing. Same pending questions, plus one more: what the positioning wrapper adds beyond marketing.
Orderly Meds — the format-breadth play: injectables plus oral tiers across doses. Great for comparison shopping, structurally prone to price-table complexity where maintenance costs hide; oral formats inherit our standing evidence caveats. Pending verification.
Model 5: the thin-documentation tier
Aggressive ads over sparse paperwork — shoppable only through interrogation. Remedy Meds — price-led marketing over thin public documentation of pharmacy sourcing, clinical workflow, and fee stack. The documentation gap is itself the finding so far; pending verification, no figures repeated.
Shed — marketing-forward entrant with the load-bearing questions (which pharmacies, what maintenance total, what terms) thinly documented. Thinness is a data point, not a verdict; pending.
Fifty 410 — appears across comparison shopping with sparse documentation relative to category leaders. Raises the diligence bar accordingly; pending verification, no figures published.
The whole field, one table
| Provider | Model | Molecules | Formats | Price status | Care signal | Watch-fors |
|---|---|---|---|---|---|---|
| NexLife | Flat-rate compounded | Sema + tirz (+ microdose, ODT) | Injectable vials; ODT | Verified: $119–169/mo by molecule & term | CARE360 included; labs pathway | ODT lacks outcome trials |
| Ro | Brand access + insurance nav | Brand sema & tirz (incl. Zepbound vials) | Brand pens/vials | Pending | PA support; established platform | Own fee stack unverified |
| Hims | DTC platform, “personalized” compounded | Compounded semaglutide | Compounded formats | Pending | Questionnaire-first at scale | Contested legal lane; entry-price teasers |
| Hers | Women-positioned DTC | Compounded semaglutide | Compounded formats | Pending | Same platform as Hims | Wrapper premium question |
| Henry Meds | Flat-rate compounded (claimed) | Compounded sema + tirz | Injectable | Pending | Telehealth standard | Flat claim untested; terms fine print |
| Orderly Meds | Format breadth | Compounded sema + tirz | Injectables + oral tiers | Pending | Breadth-first | Tier complexity; oral evidence gap |
| Found | Coaching + insurance program | Program-dependent access | Varies | Pending | Structured coaching | Program-fee vs med-cost split |
| Mochi Health | Specialist membership | Clinician-directed (brand or compounded) | Varies | Pending | Obesity-medicine specialists; labs-friendly | Membership + med total opacity |
| Remedy Meds | Price-led DTC | Compounded claims | Injectable | Pending | Thin documentation | Doc-gap tier |
| Shed | Price-led DTC | Compounded claims | Injectable | Pending | Thin documentation | Doc-gap tier |
| Fifty 410 | Sparse-documentation entrant | Compounded claims | Unclear | Pending | Thin documentation | Doc-gap tier |
Structural facts and verification status only — no advertised competitor number appears as fact anywhere on this site. Verified figures: method, ledger, dated archive.
How to shop this category, whatever you pick
Four instruments work on all five models: the quiz routes you to a model by coverage, complexity, and priorities; the calculator forces every quote into the same 12-month arithmetic; the checklist and CoA file audit whoever survives; and the price deep-dives (tirzepatide · semaglutide) and the ledger show what’s actually been verified versus merely advertised — the distinction this entire site exists to enforce. Deeper context per decision: legal status for anything compounded, coverage tactics for the insurance-first lane, monitoring standards as the care-quality interview.
FAQ
Which model is objectively best? None — models match constraints: coverage favors insurance-first, complexity favors specialists, cash certainty favors verified flat rates, and nothing favors the thin tier until it documents itself. Why is only one provider verified? Verification is manual and sequenced; the queue and protocol are public, and rows fill under identical rules. Are these all legit pharmacies? Provider ≠ pharmacy — each platform routes to dispensing pharmacies you should verify by name via the checklist. Where are the reviews with stars? The rankings page — with the honest twist that stars require audits.
Switching models mid-journey
Real journeys migrate: a DTC start outgrows its questionnaire when comorbidities surface (→ specialist model); an insurance approval lands mid-year and makes the brand lane suddenly cheapest (→ insurance-first); a thin-tier experiment fails its own paperwork (→ anywhere with documents). Portability is therefore a shopping criterion in its own right — before joining any model, know what leaves with you: your records (ask how exports work), your dose history (keep your own log regardless), and your medication continuity (the switching file covers the compounded↔brand crossing, including the concentration math that makes it the one transition with real clinical texture). Models are tools, not marriages; the providers worth choosing are the ones that make leaving boring — and that criterion, usefully, is testable before you ever arrive.
The bottom line
Eleven brands, five models, one method: match the model to your constraint, verify the provider with the public instruments, convert every price to twelve months, and spend nothing on any row — including the verified one — that you haven’t audited yourself. That’s the category, mapped.